160 related articles for article (PubMed ID: 3832745)
1. [Results of a phase II study on the treatment of hairy cell leukemias with various doses of alpha-2-recombinant interferon].
Aulitzky W; Gastl G; Troppmair J; Tilg H; Abbrederis K; Nerl C; Flener R; Rokos H; Huber C
Acta Med Austriaca; 1985; 12(5):115-21. PubMed ID: 3832745
[TBL] [Abstract][Full Text] [Related]
2. Comparison of clinical efficacy and toxicity of conventional and optimum biological response modifying doses of interferon alpha-2C in the treatment of hairy cell leukemia: a retrospective analysis of 39 patients.
Gastl G; Werter M; De Pauw B; Nerl C; Aulitzky W; von Lüttichau I; Tilg H; Thaler J; Lang A; Abbrederis K
Leukemia; 1989 Jun; 3(6):453-60. PubMed ID: 2725061
[TBL] [Abstract][Full Text] [Related]
3. A biological approach to optimize interferon treatment in hairy cell leukemia.
Gastl G; Aulitzky W; Tilg H; Nachbaur K; Troppmair J; Flener R; Huber C
Immunobiology; 1986 Sep; 172(3-5):262-8. PubMed ID: 3804368
[TBL] [Abstract][Full Text] [Related]
4. [Interferon-alpha in the treatment of hematologic neoplasms].
Aulitzky W; Gastl G; Tilg H; Troppmair J; Leiter E; Geissler D; Flener R; Huber C
Wien Med Wochenschr; 1986 Apr; 136(7-8):172-81. PubMed ID: 3524022
[TBL] [Abstract][Full Text] [Related]
5. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
6. Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
Huber C; Aulitzky W; Tilg H; von Lüttichau I; Troppmair J; Nachbauer K; Gastl G
Leukemia; 1987 Apr; 1(4):355-7. PubMed ID: 3669762
[TBL] [Abstract][Full Text] [Related]
7. Recombinant alpha-interferon (alpha-IFN) for progressive hairy-cell leukemia (HCL): a study in previously untreated nonsplenectomized patients.
Schwarzinger I; Bettelheim P; Chott A; Herold C; Hinterberger W; Köller U; Kos M; Neumann E; Radaszkiewicz T; Lechner K
Wien Klin Wochenschr; 1988 Jan; 100(2):47-51. PubMed ID: 3348041
[TBL] [Abstract][Full Text] [Related]
8. [Effect of interferon-alpha 2 (E. coli) in hairy cell leukemia].
Hofmann V; Scheel A; Schwarzmeier J; Talstad I; Varini M; Kaplan S; Sauter C; Fehr J
Schweiz Med Wochenschr; 1985 Feb; 115(7):235-8. PubMed ID: 3872477
[TBL] [Abstract][Full Text] [Related]
9. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
10. Phase I-II study of continuous-infusion high-dose human lymphoblastoid interferon and the in vitro sensitivity of leukemic progenitors in nonlymphocytic leukemia.
Mirro J; Dow LW; Kalwinsky DK; Dahl GV; Weck P; Whisnant J; Murphy SB
Cancer Treat Rep; 1986 Mar; 70(3):363-7. PubMed ID: 3456833
[TBL] [Abstract][Full Text] [Related]
11. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D
Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434
[TBL] [Abstract][Full Text] [Related]
12. Hairy cell leukemia: a model for studying the B cell family of diseases.
Al-Katib A; Berman E; Black P; Koziner B
Semin Oncol; 1986 Dec; 13(4 Suppl 5):48-54. PubMed ID: 3492047
[TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of a synthetic mutant of beta-interferon.
Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
[TBL] [Abstract][Full Text] [Related]
14. Recombinant alpha-2 interferon in the treatment of hairy cell leukemia.
Thompson JA; Brady J; Kidd P; Fefer A
Cancer Treat Rep; 1985; 69(7-8):791-3. PubMed ID: 4016788
[TBL] [Abstract][Full Text] [Related]
15. Altered tryptophan and neopterin metabolism in cancer patients treated with recombinant interleukin 2.
Brown RR; Lee CM; Kohler PC; Hank JA; Storer BE; Sondel PM
Cancer Res; 1989 Sep; 49(17):4941-4. PubMed ID: 2788032
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation by recombinant interferon-alpha 2 in a phase I trial in patients with lymphoproliferative malignancies.
Ozer H; Gavigan M; O'Malley J; Thompson D; Dadey B; Nussbaum-Blumenson A; Snider C; Rudnick S; Ferraresi R; Norred S
J Biol Response Mod; 1983; 2(6):499-515. PubMed ID: 6607323
[TBL] [Abstract][Full Text] [Related]
17. Rapid improvement in a terminal case of hairy cell leukemia treated with a new human recombinant interferon, IFN-alpha-C.
Aderka D; Levo Y; Rahmani R; Mory Y; Vaks B; Horowitz O; Doerner T; Shoham J; Wallach D; Revel M
Isr J Med Sci; 1985 Dec; 21(12):977-81. PubMed ID: 4093298
[TBL] [Abstract][Full Text] [Related]
18. [Results of a multicenter study of the efficacy of recombinant alpha-2c interferon in hairy cell leukemia].
Werter MJ; Bogman MJ; Janssen JT; de Pauw BE; Haanen CA
Ned Tijdschr Geneeskd; 1987 Nov; 131(46):2081-5. PubMed ID: 3683637
[No Abstract] [Full Text] [Related]
19. Hairy cell leukemia: an interferon deficient disease?
Hofmann V; Fehr J; Sauter C; Ottino J
Cancer Treat Rev; 1985 Dec; 12 Suppl B():33-7. PubMed ID: 3833328
[TBL] [Abstract][Full Text] [Related]
20. Effects of interferon-alpha on macrophage activation in patients with ovarian carcinoma and cervical dysplasia.
Fuith LC; Fuchs D; Hausen A; Hetzel H; Reibnegger G; Werner ER; Wachter H
J Clin Lab Immunol; 1989 Jun; 29(2):65-9. PubMed ID: 2632803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
